{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:53:53Z","timestamp":1783400033950,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA118374"],"award-info":[{"award-number":["CA118374"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL118018"],"award-info":[{"award-number":["HL118018"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","award":["Cardio-Oncology Center of Excellence"],"award-info":[{"award-number":["Cardio-Oncology Center of Excellence"]}],"id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","award":["Cardio-Oncology Center of Excellence"],"award-info":[{"award-number":["Cardio-Oncology Center of Excellence"]}],"id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Breast cancer is the most common female cancer worldwide. Effective therapies including doxorubicin and trastuzumab have improved survival, but are associated with a substantial risk of cardiovascular disease. Mechanisms underlying cancer treatment-induced cardiotoxicity (CTC) are poorly understood and have largely focused on cardiomyocyte damage, although other cellular populations in the heart such as the cardiac endothelium, may play an important role in cardiac damage. We treated a breast tumor-bearing mouse model with doxorubicin and trastuzumab to investigate the role of the cardiac endothelium in the development of CTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Immune compromised mice were inoculated in the 4th mammary fat pad with human breast cancer cells overexpressing HER2 (BT474). When tumors were palpable, mice were treated weekly with doxorubicin (5\u2009mg\/kg) and trastuzumab (4\u2009mg\/kg). The cardiac phenotype of mice was assessed by echocardiography and histological evaluation of the heart. Cardiac vascular damage was assayed by in vivo permeability assays and primary cultures of murine cardiac endothelial cells were used to assay doxorubicin toxicity in vitro<jats:italic>.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The growth of BT474 breast tumors in Balb\/c Nude mice was suppressed upon treatment with doxorubicin and trastuzumab. Mice treated for 4\u2009months with doxorubicin and trastuzumab maintained body weights, but demonstrated an echocardiographic phenotype consistent with preserved left ventricular (LV) ejection fraction, decreased LV mass and increased filling pressures (E\/e\u2019). Histological staining with Masson\u2019s trichrome and Picrosirius red showed extensive fibrosis and increased collagen deposition in the ventricular myocardium surrounding blood vessels of treated mice compared to untreated mice. Evans blue permeability assays demonstrated increased cardiac vasculature permeability while primary cardiac endothelial cells exposed to doxorubicin in vitro showed increased cell death as compared to lung or liver endothelial cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>An orthotopic mouse model of human breast cancer in Nude mice treated with doxorubicin and trastuzumab resulted in a cardiac vascular defect accompanied by preserved LV ejection fraction, decreased LV mass, suggesting mild diastolic dysfunction and cardiac remodeling consistent with subclinical cardiotoxicity. Our data suggest that cardiac endothelium is more sensitive to doxorubicin therapy as compared to other organ endothelium and cardiac endothelial damage may correlate with breast cancer treatment-induced cardiotoxicity.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40959-021-00100-3","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T05:02:36Z","timestamp":1618808556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Damage to cardiac vasculature may be associated with breast cancer treatment-induced cardiotoxicity"],"prefix":"10.1186","volume":"7","author":[{"given":"Rebecca K.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ryeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"100_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014. Bethesda: National Cancer Institute. https:\/\/seer.cancer.gov\/csr\/1975_2014\/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017."},{"issue":"2","key":"100_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012;18(2):113\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2011.10.015.","journal-title":"J Card Fail"},{"issue":"24","key":"100_CR3","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant Trastuzumab therapy for breast Cancer. J Am Coll Cardiol. 2012;60(24):2504\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.068.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"100_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","volume":"2","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2(1):88\u201393. https:\/\/doi.org\/10.1001\/jamacardio.2016.3841.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"100_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","volume":"164","author":"SAM Gernaat","year":"2017","unstructured":"Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537\u201355. https:\/\/doi.org\/10.1007\/s10549-017-4282-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"100_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","volume":"27","author":"PT Bradshaw","year":"2016","unstructured":"Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast Cancer survivors. Epidemiology. 2016;27(1):6\u201313. https:\/\/doi.org\/10.1097\/EDE.0000000000000394.","journal-title":"Epidemiology."},{"issue":"11","key":"100_CR7","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379. https:\/\/doi.org\/10.1002\/cncr.11407.","journal-title":"Cancer."},{"issue":"6","key":"100_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCIMAGING.114.002217","volume":"7","author":"JH Jordan","year":"2014","unstructured":"Jordan JH, D'Agostino RB Jr, Hamilton CA, et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2014;7(6):872\u20139. https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.002217.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"17","key":"100_CR9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","volume":"128","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927\u201395. https:\/\/doi.org\/10.1161\/CIR.0b013e3182a88099.","journal-title":"Circulation."},{"issue":"12","key":"100_CR10","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","volume":"23","author":"SE Lipshultz","year":"2005","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629\u201336. https:\/\/doi.org\/10.1200\/JCO.2005.12.121.","journal-title":"J Clin Oncol"},{"key":"100_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.109.856310","volume":"120","author":"B Ky","year":"2009","unstructured":"Ky B, Kimmel SE, Safa RN, et al. Neuregulin-1beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120:310\u20137.","journal-title":"Circulation"},{"issue":"4","key":"100_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.yexcr.2008.08.015","volume":"315","author":"L Pentassuglia","year":"2009","unstructured":"Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta\/ErbB signaling in the heart. Exp Cell Res. 2009;315(4):627\u201337. https:\/\/doi.org\/10.1016\/j.yexcr.2008.08.015.","journal-title":"Exp Cell Res"},{"key":"100_CR13","doi-asserted-by":"publisher","first-page":"e001952","DOI":"10.1161\/CIRCIMAGING.114.001952","volume":"8","author":"H Su","year":"2015","unstructured":"Su H, Gorodny N, Gomez LF, et al. Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. Circ Cardiovasc Imaging. 2015;8:e001952.","journal-title":"Circ Cardiovasc Imaging."},{"key":"100_CR14","doi-asserted-by":"publisher","unstructured":"Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, et al. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9(12). https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.003584.","DOI":"10.1161\/CIRCIMAGING.115.003584"},{"key":"100_CR15","first-page":"1321","volume":"39","author":"M Tian","year":"2011","unstructured":"Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011;39:1321\u20136.","journal-title":"Int J Oncol"},{"issue":"3","key":"100_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5339\/gcsp.2014.43","volume":"2014","author":"RJ Widmer","year":"2014","unstructured":"Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;2014(3):291\u2013308. https:\/\/doi.org\/10.5339\/gcsp.2014.43.","journal-title":"Glob Cardiol Sci Pract"},{"key":"100_CR17","doi-asserted-by":"publisher","first-page":"12392","DOI":"10.1111\/j.1538-7836.2005.01328.x","volume":"3","author":"WC Aird","year":"2005","unstructured":"Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost. 2005;3:12392\u2013406.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"100_CR18","first-page":"967","volume":"61","author":"EY Lasfargues","year":"1978","unstructured":"Lasfargues EY, Coutinho WG, Redfield ES. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst. 1978;61(4):967\u201378.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"100_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","volume":"88","author":"MS O'Reilly","year":"1997","unstructured":"O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277\u201385. https:\/\/doi.org\/10.1016\/S0092-8674(00)81848-6.","journal-title":"Cell."},{"issue":"1","key":"100_CR20","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1038\/s41467-018-06881-z","volume":"9","author":"DH Bhang","year":"2018","unstructured":"Bhang DH, Kim BJ, Kim BG, Schadler K, Baek KH, Kim YH, et al. Testicular endothelial cells are a crtical population in the germline stem cell niche. Nat Commun. 2018;9(1):4379\u201384. https:\/\/doi.org\/10.1038\/s41467-018-06881-z.","journal-title":"Nat Commun"},{"issue":"9","key":"100_CR21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.mayocp.2018.05.001","volume":"93","author":"MA Lyle","year":"2018","unstructured":"Lyle MA, Brozovich FV. HFpEF, a disease of the vasculature: a closer look at the other half. Mayo Clin Proc. 2018;93(9):1305\u201314. https:\/\/doi.org\/10.1016\/j.mayocp.2018.05.001.","journal-title":"Mayo Clin Proc"},{"key":"100_CR22","first-page":"e50062","volume":"73","author":"M Radu","year":"2013","unstructured":"Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. J Vis Exp. 2013;73:e50062.","journal-title":"J Vis Exp"},{"issue":"2","key":"100_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.devcel.2013.06.017","volume":"26","author":"DJ Nolan","year":"2013","unstructured":"Nolan DJ, Ginsberg M, Israely E, Palikuqi B, Poulos MG, James D, et al. Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell. 2013;26(2):204\u201319. https:\/\/doi.org\/10.1016\/j.devcel.2013.06.017.","journal-title":"Dev Cell"},{"issue":"1","key":"100_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40959-019-0037-6","volume":"5","author":"AJ Favreau-Lessard","year":"2019","unstructured":"Favreau-Lessard AJ, Blasyzyk H, Jones MA, Sawyer DB, Pinz IM. Systemic and cardiac susceptibility of immune compromised mice to doxorubicin. Cardiooncology. 2019;5(1):2. https:\/\/doi.org\/10.1186\/s40959-019-0037-6.","journal-title":"Cardiooncology."},{"issue":"22","key":"100_CR25","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","volume":"26","author":"L Gianni","year":"2008","unstructured":"Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26(22):3777\u201384. https:\/\/doi.org\/10.1200\/JCO.2007.14.9401.","journal-title":"J Clin Oncol"},{"key":"100_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"15","author":"TM Suter","year":"2013","unstructured":"Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;15:1102\u201311.","journal-title":"Eur Heart J"},{"key":"100_CR27","doi-asserted-by":"crossref","first-page":"e003806","DOI":"10.1161\/CIRCHEARTFAILURE.116.003806","volume":"0","author":"AB Gevaert","year":"2017","unstructured":"Gevaert AB, Shakeri H, Leloup AJ, Van Hove CE, DeMeyer GRY, Vrints CJ, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. Circ Heart Fail. 2017;0:e003806.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"100_CR28","doi-asserted-by":"publisher","first-page":"H705","DOI":"10.1152\/ajpheart.00370.2019","volume":"317","author":"SN Hader","year":"2019","unstructured":"Hader SN, Zinkevich N, Norwood Toro LE, Kriegel AJ, Kong A, Freed JK, et al. Detrimental effects of chemotherapy on human coronary microvascular function. Am J Physiol Heart Circ Physiol. 2019;317(4):H705\u201310. https:\/\/doi.org\/10.1152\/ajpheart.00370.2019.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"100_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fcvm.2019.00015","volume":"6","author":"H Zeng","year":"2019","unstructured":"Zeng H, Chan J-X. Microvascular rarefaction and heart failure with preserved ejection fraction. Front Cardiovasc Med. 2019;6:15. https:\/\/doi.org\/10.3389\/fcvm.2019.00015.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"100_CR30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1242\/bio.020362","volume":"5","author":"EL Wilkinson","year":"2016","unstructured":"Wilkinson EL, Sidaway JE, Cross MJ. Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability. Biology Open. 2016;5(10):1362\u201370. https:\/\/doi.org\/10.1242\/bio.020362.","journal-title":"Biology Open"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-021-00100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-021-00100-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-021-00100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T16:56:18Z","timestamp":1671900978000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-021-00100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1186\/s40959-021-00100-3","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"22 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}